On May 4, 2026, Celcuity Inc. (NASDAQ: CELC) garnered a “Buy” rating from Swayampakula Ramakanth at HC Wainwright & Co., reflecting the firm’s optimistic outlook for the biopharmaceutical company’s stock. With a current price of $121.35 and an analyst price target of $165, this recommendation signals significant upside potential for investors. The positive sentiment comes amid a remarkable performance trajectory that underscores the company’s appeal in the market.
Recent Price Action
In the last week, CELC has demonstrated noteworthy price movements, notably a change of 23.79, representing a substantial 18.9% increase. Such a rise indicates a robust bullish sentiment among investors, buoyed by favorable market conditions and the recent analyst upgrade. However, the stock’s 52-week high of $136.93 suggests it has yet to reach its full potential, falling short by nearly $15, while the low of $7.64 reflects its volatility—attributable to factors ranging from market trends to company-specific developments. With a market capitalization of approximately $7.22 billion and a relatively low beta of 0.422, CELC appears to exhibit a steady but dynamic trading behavior, with current volume at 355,093 and an average volume of 779,190 suggesting ample activity in its shares.
[chart type=’price’ value=’CELC’]
Historical Performance
Celcuity’s performance metrics portray a company on a notable upward trend. Over the last 30 days, the stock has increased by 6.4%, while a quarterly performance jump of 102.83% highlights its capacity for rapid appreciation. Impressively, over the past year, CELC has surged by 836.8%. Despite potential price swings, evidenced by a weekly volatility of 7.19% and a monthly volatility of 4.76%, the stock has managed to captivate investor interest consistently. Average volumes further affirm this trend, with a 10-day average of 772,520 and a 3-month average of 686,388.
[chart type=’performance’ value=’CELC’]
Earnings Analysis
Celcuity recently reported earnings that beat expectations, recording an actual EPS of -$0.97 compared to an estimated -$1.06. This results in an EPS surprise of 8.49%, signifying a stronger-than-anticipated performance that could bolster investor confidence. For context, the preceding earnings report from November 2025 saw an actual EPS of -$0.92 against an estimate of -$1.05, marking a surprise of -12.38%, which had posed some concerns at the time. The recent improvement in earnings reports can be interpreted as a positive trend, indicating the company’s potential for recovery and growth.
[chart type=’income-bar-chart’ value=’CELC’]
Consensus Ratings
The recent unanimity in analyst sentiment is noteworthy; Celcuity boasts a total of nine ratings from analysts, all categorized as “Buy.” The average price target stands at approximately $143.11, with a high target matching HC Wainwright’s aggressive projection of $165 and a lower bound of $122. This broad consensus reflects strong confidence in the company’s ability to outperform the market and aligns with recent stock price movements, suggesting that analysts see significant value in CELC.
[chart type=’analyst-ratings’ value=’CELC’]
Stock Grading or Fundamental View
Celcuity Inc. currently holds a Stocks Telegraph Grading Score of 50, which is indicative of a balanced investment profile based on an analysis of its financial health and market dynamics. This score reflects moderate strength in fundamentals, but also implies that there may be room for improvement as the company navigates its operational challenges ahead.
[chart type=’st-cards’ value=’CELC’]
Conclusion
For investors considering Celcuity Inc. (CELC), the stock presents itself as an attractive candidate for those with a long-term growth orientation, particularly given its potential for substantial upside as projected by analysts. However, prospective investors should remain cognizant of the inherent risks associated with the biotech sector, including volatility and regulatory hurdles. The encouraging recent earnings performance and unanimous analyst support present a compelling narrative, making CELC a stock worth monitoring closely as it continues to evolve within its competitive landscape.